Tim Ring

Co-Founder/Co-Chairman

Mr. Ring co-founded TEAMFund to foster the development of world-class medical technologies suited to the needs of low-to-middle income populations. He currently serves as a Director on the Boards of Becton Dickinson (NYSE: BDX) and Quest Diagnostics (NYSE: DGX). Before TEAMFund, he served as Chairman and CEO of C.R. Bard from 2003 through its sale to Becton Dickinson for $24 billion in 2017.

Prior Experience

Board Director, CIT Holdings
Board Chairman, Healthcare Institute of New Jersey
Foundation Trustee, University of Medicine and Dentistry of New Jersey
General Manager Australia, Indonesia (and other roles), Abbott Laboratories

Education

B.S., Cornell University

Led $24B acquisition of CR Bard to Becton Dickinson, April 2017 (largest M&A transaction in 2017 to date)
Grew Bard ~10x in value from $2.46B market cap since taking CEO role in August 2003
19% CAGR in emerging markets, growing annual revenue from $39M to $461M
Over 400 new products launched globally
Led 100+ strategic acquisitions, over $3B aggregate deal value
15-year average acquisition ROI of 22.3%